The estimated Net Worth of Robert Joseph Bujarski is at least $11.9 Milione dollars as of 20 May 2020. Mr. Bujarski owns over 20,000 units of QuidelOrtho stock worth over $600,228 and over the last 19 years he sold QDEL stock worth over $9,887,103. In addition, he makes $1,391,320 as Chief Operating Officer at QuidelOrtho.
Sign up
Mr. Bujarski QDEL stock SEC Form 4 insiders trading
Robert has made over 10 trades of the QuidelOrtho stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of QDEL stock worth $3,788,200 on 20 May 2020.
The largest trade he's ever made was exercising 110,704 units of QuidelOrtho stock on 15 December 2017 worth over $2,299,322. On average, Robert trades about 4,563 units every 30 days since 2005. As of 20 May 2020 he still owns at least 13,383 units of QuidelOrtho stock.
You can see the complete history of Mr. Bujarski stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Bujarski biography
Robert Joseph Bujarski J.D. serves as Chief Operating Officer of the Company. Mr. Bujarski also previously served as our Senior Vice President, General Counsel and Corporate Secretary through August 2009 and joined Quidel in 2005 as our General Counsel and Vice President. Mr. Bujarski was an associate attorney with the law firm of Gibson, Dunn & Crutcher LLP in its transactions practice group from October 2001 to July 2005. Mr. Bujarski received his B.A. degree in 1991 and his law degree in 2001 from the University of Arizona.
What is the salary of Robert Bujarski?
As the Chief Operating Officer of QuidelOrtho, the total compensation of Robert Bujarski at QuidelOrtho is $1,391,320. There are 4 executives at QuidelOrtho getting paid more, with Douglas Bryant having the highest compensation of $4,168,770.
How old is Robert Bujarski?
Robert Bujarski is 51, he's been the Chief Operating Officer of QuidelOrtho since 2020. There are 24 older and 3 younger executives at QuidelOrtho. The oldest executive at QuidelOrtho Corporation is Mary Polan, 76, who is the Independent Director.
Insiders trading at QuidelOrtho
Over the last 21 years, insiders at QuidelOrtho have traded over $509,235,797 worth of QuidelOrtho stock and bought 304,015 units worth $10,385,234 . The most active insiders traders include Jack W Schuler, Matthew Strobeck e Group Inc.Carlyle Holdings .... On average, QuidelOrtho executives and independent directors trade stock every 16 days with the average trade being worth of $1,246,606. The most recent stock trade was executed by Group Inc.Carlyle Holdings ... on 9 August 2024, trading 74,134 units of QDEL stock currently worth $3,078,785.
What does QuidelOrtho do?
QuidelOrtho Corporation is a major American manufacturer of diagnostic healthcare products that are sold worldwide.
What does QuidelOrtho's logo look like?
Complete history of Mr. Bujarski stock trades at QuidelOrtho
QuidelOrtho executives and stock owners
QuidelOrtho executives and other stock owners filed with the SEC include:
-
Douglas Bryant,
President, Chief Executive Officer, Director -
Douglas C. Bryant,
Pres, CEO & Director -
Randall Steward,
Chief Financial Officer -
Michael Abney,
Senior Vice President - Distribution -
Robert Bujarski,
Chief Operating Officer -
Ratan Borkar,
Senior Vice President - International Commercial Operations -
Werner Kroll,
Senior Vice President - R&D -
Edward Russell,
Senior Vice President - Business Development -
Robert J. Bujarski,
Chief Operating Officer -
Randall J. Steward,
Chief Financial Officer -
Dr. Werner Kroll,
Sr. VP of R&D -
Ratan S. Borkar,
Sr. VP of International Commercial Operations -
Robert J. Bujarski J.D.,
Pres & COO -
Kenneth Buechler,
Independent Chairman of the Board -
Edward Michael,
Independent Director -
Ken Widder,
Independent Director -
Charles Slacik,
Independent Director -
Matthew Strobeck,
Independent Director -
Mary Polan,
Independent Director -
Kathy Ordonez,
Independent Director -
Ruben Argueta,
Director - Investor Relations -
Ann Rhoads,
Director -
Karen Gibson,
Senior Vice President, Information Systems and Business Transformation -
Dr. Chockalingam Palaniappan Ph.D.,
Chief Innovation Officer -
Patrick E. Klein,
Chief Admin. Officer -
Louise Brandy,
Chief Information Officer -
Rhys de Callier,
VP of Strategy & Portfolio Management -
Dr. Johannes Kehle,
Pres of AnDiaTec Division -
Phillip S. Askim,
VP, Associate Gen. Counsel & Sec. -
Michael S. Iskra,
Chief Commercial Officer -
Joseph M. Busky CPA,
Chief Financial Officer -
Karen C. Gibson,
Sr. VP of Digital Health Bus. Unit -
Edward Keith Russell,
Sr. VP of Bus. Devel. -
Michael Donald Abney Jr.,
Sr. VP of North American Sales & Distribution -
Michelle A. Hodges,
Sr. VP & Gen. Counsel -
Group Inc.Carlyle Holdings ...,
-
Thomas D Brown,
Director -
Rodney F Dammeyer,
Director -
John Tamerius,
Sr. VP - Clinical/Reg Affairs -
Patrick Klein,
Chief Administrative Officer -
Louise Brandy,
SVP, Chief Information Officer -
Tamara A. Ranalli,
SVP, Molecular Bus. Unit -
Mark W Smits,
SVP-Commercial Operations -
Mark Pulido,
Director -
John Matthew Radak,
Chief Financial Officer -
Timothy Todd Stenzel,
Chief Science Officer -
Scot M Mc Leod,
Sr. VP - Operations -
Caren L Mason,
President and CEO -
Jack W Schuler,
Director -
Thomas James Foley,
Chief Technical Officer -
David R. Scholl,
Senior Vice President -
Richard C Iii Tarbox,
Sr. VP - Corporate Development -
Matthew T Heindel,
Sr. VP - Global Sales & Mrktg -
Douglas S Harrington,
Director -
Faye Wattleton,
Director -
Mark Paiz,
Senior Vice President -
Thomas A Glaze,
Director -
Paul E Landers,
Sr. V.P., CFO and Secretary -
S Wayne Kay,
President & CEO -
William J. Ferenczy,
SVP, Cardio/Metabolic Unit -
Michael S. Iskra,
EVP & CCO -
Christopher M Smith,
Director -
Joseph D Jr. Wilkins,
-
Evelyn S Dilsaver,
-
Joseph M Busky,
Chief Financial Officer -
James Prutow,
-
Michelle A. Hodges,
SVP, General Counsel